Revefenacin | hsa00030 | Pentose phosphate pathway | 4.69E-04 | 4 | P60891, P51854, P52209, P37837 | PRPS1, TKTL1, PGD, TALDO1 | More | |
Revefenacin | hsa00220 | Arginine biosynthesis | 1.85E-03 | 2 | P05089, P49448 | ARG1, GLUD2 | More | |
Revefenacin | hsa00310 | Lysine degradation | 3.15E-02 | 2 | Q96KQ7, P51648 | EHMT2, ALDH3A2 | More | |
Revefenacin | hsa00500 | Starch and sucrose metabolism | 9.35E-03 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | |
Revefenacin | hsa00510 | N-Glycan biosynthesis | 3.15E-02 | 2 | P15907, Q9NR34 | ST6GAL1, MAN1C1 | More | |
Revefenacin | hsa00520 | Amino sugar and nucleotide sugar metabolism | 2.24E-02 | 3 | Q16222, Q9Y223, P06865 | UAP1, GNE, HEXA | More | |
Revefenacin | hsa00600 | Sphingolipid metabolism | 3.76E-02 | 1 | P15289 | ARSA | More | |
Revefenacin | hsa00630 | Glyoxylate and dicarboxylate metabolism | 1.13E-02 | 2 | P40925, P15104 | MDH1, GLUL | More | |
Revefenacin | hsa00830 | Retinol metabolism | 3.93E-02 | 3 | P00352, Q9BPW9, O75911 | ALDH1A1, DHRS9, DHRS3 | More | |
Revefenacin | hsa00983 | Drug metabolism - other enzymes | 2.45E-02 | 3 | P20839, P32320, P05164 | IMPDH1, CDA, MPO | More | |
Revefenacin | hsa01230 | Biosynthesis of amino acids | 2.19E-02 | 4 | P51854, P60891, P05089, P37837 | TKTL1, PRPS1, ARG1, TALDO1 | More | |
Revefenacin | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 1.82E-02 | 1 | P08069 | IGF1R | More | |
Revefenacin | hsa01522 | Endocrine resistance | 2.16E-02 | 1 | P08069 | IGF1R | More | |
Revefenacin | hsa01523 | Antifolate resistance | 1.68E-02 | 2 | Q92820, P04818 | GGH, TYMS | More | |
Revefenacin | hsa02010 | ABC transporters | 4.48E-02 | 1 | Q8IZY2 | ABCA7 | More | |
Revefenacin | hsa03040 | Spliceosome | 2.10E-04 | 10 | O60508, P08579, P26368, Q13595, Q01130, P84103, Q13243, P11142, Q9Y2W2, O75643 | CDC40, SNRPB2, U2AF2, TRA2A, SFRS2, SFRS3, SFRS5, HSPA8, WBP11, ASCC3L1 | More | |
Revefenacin | hsa03430 | Mismatch repair | 4.38E-02 | 1 | P20585 | MSH3 | More | |
Revefenacin | hsa04010 | MAPK signaling pathway | 4.15E-02 | 1 | P08069 | IGF1R | More | |
Revefenacin | hsa04014 | Ras signaling pathway | 3.65E-02 | 1 | P08069 | IGF1R | More | |
Revefenacin | hsa04015 | Rap1 signaling pathway | 5.18E-04 | 3 | P08069, P06213, O00522 | IGF1R, INSR, KRIT1 | More | |
Revefenacin | hsa04060 | Cytokine-cytokine receptor interaction | 5.34E-03 | 11 | P14784, P27930, P14778, P26842, Q06643, Q13651, P25024, Q9UBD3, P47992, P09341, P01730 | IL2RB, IL1R2, IL1R1, CD27, LTB, IL10RA, CXCR1, XCL2, XCL1, CXCL1, CD4 | More | |
Revefenacin | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 1.32E-02 | 6 | P09341, P25024, P47992, Q9UBD3, Q13651, P14784 | CXCL1, CXCR1, XCL1, XCL2, IL10RA, IL2RB | More | |
Revefenacin | hsa04062 | Chemokine signaling pathway | 6.73E-03 | 9 | P25024, P09341, P47992, Q9UBD3, P07948, P63218, P50151, P43250, Q08881 | CXCR1, CXCL1, XCL1, XCL2, LYN, GNG5, GNG10, GRK6, ITK | More | |
Revefenacin | hsa04064 | NF-kappa B signaling pathway | 3.17E-07 | 14 | P10415, O00463, P14778, P01375, Q04759, Q9UDY8, Q13077, Q16548, P07948, P06239, Q13315, P24522, P09341, Q06643 | BCL2, TRAF5, IL1R1, TNF, PRKCQ, MALT1, TRAF1, BCL2A1, LYN, LCK, ATM, GADD45A, CXCL1, LTB | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P42681 | TXK | Tyrosine-protein kinase TXK | P10415 | BCL2 | Apoptosis regulator Bcl-2 | 0.716 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P10415 | BCL2 | Apoptosis regulator Bcl-2 | 0.744 | P42681 | TXK | Tyrosine-protein kinase TXK | O00463 | TRAF5 | TNF receptor-associated factor 5 | 0.827 | P06239 | LCK | Tyrosine-protein kinase Lck | O00463 | TRAF5 | TNF receptor-associated factor 5 | 0.718 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | O00463 | TRAF5 | TNF receptor-associated factor 5 | 0.945 | P51813 | BMX | Cytoplasmic tyrosine-protein kinase BMX | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.735 | P06239 | LCK | Tyrosine-protein kinase Lck | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.782 | P51813 | BMX | Cytoplasmic tyrosine-protein kinase BMX | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.854 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P01375 | TNF | Tumor necrosis factor | -0.79 | P42681 | TXK | Tyrosine-protein kinase TXK | Q04759 | PRKCQ | Protein kinase C theta type | 0.876 | P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q04759 | PRKCQ | Protein kinase C theta type | 0.803 | P51813 | BMX | Cytoplasmic tyrosine-protein kinase BMX | Q04759 | PRKCQ | Protein kinase C theta type | -0.737 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q9UDY8 | MALT1 | Mucosa-associated lymphoid tissue lymphoma translocation protein 1 | 0.721 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q13077 | TRAF1 | TNF receptor-associated factor 1 | 0.83 | P42681 | TXK | Tyrosine-protein kinase TXK | Q16548 | BCL2A1 | Bcl-2-related protein A1 | -0.756 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q16548 | BCL2A1 | Bcl-2-related protein A1 | -0.877 | P51813 | BMX | Cytoplasmic tyrosine-protein kinase BMX | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.742 | P06239 | LCK | Tyrosine-protein kinase Lck | P07948 | LYN | Tyrosine-protein kinase Lyn | -0.701 | P42681 | TXK | Tyrosine-protein kinase TXK | P06239 | LCK | Tyrosine-protein kinase Lck | 0.734 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P06239 | LCK | Tyrosine-protein kinase Lck | 0.774 | P51813 | BMX | Cytoplasmic tyrosine-protein kinase BMX | P06239 | LCK | Tyrosine-protein kinase Lck | -0.791 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q13315 | ATM | Serine-protein kinase ATM | 0.752 | P42681 | TXK | Tyrosine-protein kinase TXK | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | -0.79 | P06239 | LCK | Tyrosine-protein kinase Lck | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | -0.724 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | -0.75 | P51813 | BMX | Cytoplasmic tyrosine-protein kinase BMX | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.758 | P42681 | TXK | Tyrosine-protein kinase TXK | P09341 | CXCL1 | Growth-regulated alpha protein | -0.881 | P06239 | LCK | Tyrosine-protein kinase Lck | P09341 | CXCL1 | Growth-regulated alpha protein | -0.805 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P09341 | CXCL1 | Growth-regulated alpha protein | -0.802 | P51813 | BMX | Cytoplasmic tyrosine-protein kinase BMX | P09341 | CXCL1 | Growth-regulated alpha protein | 0.78 | P06239 | LCK | Tyrosine-protein kinase Lck | Q06643 | LTB | Lymphotoxin-beta | 0.846 |
|
Revefenacin | hsa04066 | HIF-1 signaling pathway | 2.16E-02 | 1 | P08069 | IGF1R | More | |
Revefenacin | hsa04068 | FoxO signaling pathway | 1.99E-02 | 1 | P08069 | IGF1R | More | |
Revefenacin | hsa04110 | Cell cycle | 6.63E-04 | 6 | P06493, O60566, P30304, P33981, P42773, P01106 | CDK1, BUB1B, CDC25A, TTK, CDKN2C, MYC | More | |
Revefenacin | hsa04114 | Oocyte meiosis | 2.99E-02 | 1 | P08069 | IGF1R | More | |
Revefenacin | hsa04140 | Autophagy - animal | 9.37E-03 | 6 | P08069, P22694, Q14643, P10415, Q9H1Y0, Q04759 | IGF1R, PRKACB, ITPR1, BCL2, ATG5, PRKCQ | More | |
Revefenacin | hsa04142 | Lysosome | 2.01E-03 | 6 | P22304, P38571, Q13510, Q9UJJ9, P07602, P49279 | IDS, LIPA, ASAH1, GNPTG, PSAP, SLC11A1 | More | |
Revefenacin | hsa04144 | Endocytosis | 1.09E-03 | 12 | Q13191, P0DMV8, P11142, Q9H444, P62491, P25024, P43250, Q8WU79, Q14161, P14784, Q9UMY4, Q9Y5X3 | CBLB, HSPA1A, HSPA8, CHMP4B, RAB11A, CXCR1, GRK6, SMAP1L, GIT2, IL2RB, SNX12, SNX5 | More | |
Revefenacin | hsa04145 | Phagosome | 3.69E-02 | 7 | O75015, Q15080, P05164, P78380, O60603, P35443, P13765 | FCGR3B, NCF4, MPO, OLR1, TLR2, THBS4, HLA-DOB | More | |
Revefenacin | hsa04150 | mTOR signaling pathway | 2.32E-02 | 1 | P08069 | IGF1R | More | |
Revefenacin | hsa04152 | AMPK signaling pathway | 1.99E-02 | 1 | P08069 | IGF1R | More | |
Revefenacin | hsa04211 | Longevity regulating pathway | 2.16E-02 | 1 | P08069 | IGF1R | More | |
Revefenacin | hsa04213 | Longevity regulating pathway - multiple species | 9.98E-03 | 3 | P08069, Q08828, P0DMV8 | IGF1R, ADCY1, HSPA1A | More | |
Revefenacin | hsa04270 | Vascular smooth muscle contraction | 1.53E-02 | 4 | P0DP23, Q08828, P35579, P35318 | CALM1, ADCY1, MYH9, ADM | More | |
Revefenacin | hsa04340 | Hedgehog signaling pathway | 3.93E-02 | 3 | P22694, Q13635, P10415 | PRKACB, PTCH1, BCL2 | More | |
Revefenacin | hsa04510 | Focal adhesion | 3.48E-02 | 1 | P08069 | IGF1R | More | |
Revefenacin | hsa04520 | Adherens junction | 8.29E-03 | 1 | P08069 | IGF1R | More | |
Revefenacin | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 1.99E-02 | 1 | P08069 | IGF1R | More | |
Revefenacin | hsa04610 | Complement and coagulation cascades | 1.14E-05 | 2 | P00734, P0C0L4 | F2, C4A | More | |
Revefenacin | hsa04612 | Antigen processing and presentation | 2.02E-03 | 8 | P13765, P48382, P01730, P26715, P26717, Q13241, P01732, P01375 | HLA-DOB, RFX5, CD4, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | |
Revefenacin | hsa04640 | Hematopoietic cell lineage | 1.56E-05 | 13 | P13612, P14778, P27930, P15144, P25063, P07766, P09693, P01732, P01730, P06127, P09564, P13765, P01375 | ITGA4, IL1R1, IL1R2, ANPEP, CD24, CD3E, CD3G, CD8A, CD4, CD5, CD7, HLA-DOB, TNF | More | |
Revefenacin | hsa04650 | Natural killer cell mediated cytotoxicity | 6.35E-06 | 10 | P01375, P06239, O60880, P20963, Q13241, P26718, O14931, O75015, P26717, P26715 | TNF, LCK, SH2D1A, CD247, KLRD1, KLRK1, NCR3, FCGR3B, KLRC2, KLRC1 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P01375 | TNF | Tumor necrosis factor | -0.79 | P42681 | TXK | Tyrosine-protein kinase TXK | P06239 | LCK | Tyrosine-protein kinase Lck | 0.734 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P06239 | LCK | Tyrosine-protein kinase Lck | 0.774 | P42681 | TXK | Tyrosine-protein kinase TXK | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.881 | P06239 | LCK | Tyrosine-protein kinase Lck | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.906 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.862 | P42681 | TXK | Tyrosine-protein kinase TXK | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.811 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.839 | P42681 | TXK | Tyrosine-protein kinase TXK | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.888 | P06239 | LCK | Tyrosine-protein kinase Lck | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.758 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.852 | P42681 | TXK | Tyrosine-protein kinase TXK | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.869 | P06239 | LCK | Tyrosine-protein kinase Lck | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.886 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.922 | P06239 | LCK | Tyrosine-protein kinase Lck | O14931 | NCR3 | Natural cytotoxicity triggering receptor 3 | 0.732 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | -0.778 | P42681 | TXK | Tyrosine-protein kinase TXK | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.901 | P06239 | LCK | Tyrosine-protein kinase Lck | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.756 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.943 | P42681 | TXK | Tyrosine-protein kinase TXK | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.901 | P06239 | LCK | Tyrosine-protein kinase Lck | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.756 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.943 |
|
Revefenacin | hsa04658 | Th1 and Th2 cell differentiation | 9.50E-14 | 13 | Q04759, P07766, P20963, P09693, Q16539, P01730, P06239, Q14765, P23771, Q9UL17, P14784, P13765, Q13761 | PRKCQ, CD3E, CD247, CD3G, MAPK14, CD4, LCK, STAT4, GATA3, TBX21, IL2RB, HLA-DOB, RUNX3 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P42681 | TXK | Tyrosine-protein kinase TXK | Q04759 | PRKCQ | Protein kinase C theta type | 0.876 | P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q04759 | PRKCQ | Protein kinase C theta type | 0.803 | P51813 | BMX | Cytoplasmic tyrosine-protein kinase BMX | Q04759 | PRKCQ | Protein kinase C theta type | -0.737 | P07948 | LYN | Tyrosine-protein kinase Lyn | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | -0.824 | P06239 | LCK | Tyrosine-protein kinase Lck | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.928 | P51813 | BMX | Cytoplasmic tyrosine-protein kinase BMX | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | -0.755 | P42681 | TXK | Tyrosine-protein kinase TXK | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.811 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.839 | P51813 | BMX | Cytoplasmic tyrosine-protein kinase BMX | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.778 | P42681 | TXK | Tyrosine-protein kinase TXK | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.838 | P06239 | LCK | Tyrosine-protein kinase Lck | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.752 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.813 | P51813 | BMX | Cytoplasmic tyrosine-protein kinase BMX | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.802 | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | P51813 | BMX | Cytoplasmic tyrosine-protein kinase BMX | P01730 | CD4 | T-cell surface glycoprotein CD4 | -0.857 | P42681 | TXK | Tyrosine-protein kinase TXK | P06239 | LCK | Tyrosine-protein kinase Lck | 0.734 | P07948 | LYN | Tyrosine-protein kinase Lyn | P06239 | LCK | Tyrosine-protein kinase Lck | -0.701 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P06239 | LCK | Tyrosine-protein kinase Lck | 0.774 | P51813 | BMX | Cytoplasmic tyrosine-protein kinase BMX | P06239 | LCK | Tyrosine-protein kinase Lck | -0.791 | P42681 | TXK | Tyrosine-protein kinase TXK | Q14765 | STAT4 | Signal transducer and activator of transcription 4 | 0.771 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q14765 | STAT4 | Signal transducer and activator of transcription 4 | 0.904 | P42681 | TXK | Tyrosine-protein kinase TXK | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.856 | P06239 | LCK | Tyrosine-protein kinase Lck | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.77 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.784 | P42681 | TXK | Tyrosine-protein kinase TXK | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.849 | P07948 | LYN | Tyrosine-protein kinase Lyn | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.719 | P06239 | LCK | Tyrosine-protein kinase Lck | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.866 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.884 | P07948 | LYN | Tyrosine-protein kinase Lyn | P14784 | IL2RB | Interleukin-2 receptor subunit beta | -0.771 | P06239 | LCK | Tyrosine-protein kinase Lck | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.727 | P42681 | TXK | Tyrosine-protein kinase TXK | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.89 | P06239 | LCK | Tyrosine-protein kinase Lck | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.777 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.85 | P07948 | LYN | Tyrosine-protein kinase Lyn | Q13761 | RUNX3 | Runt-related transcription factor 3 | -0.855 | P06239 | LCK | Tyrosine-protein kinase Lck | Q13761 | RUNX3 | Runt-related transcription factor 3 | 0.85 |
|
Revefenacin | hsa04659 | Th17 cell differentiation | 1.13E-11 | 15 | Q04759, Q16539, P01730, P06239, P14784, P13765, P14778, Q9HBE5, Q9UL17, P23771, Q13485, P08238, P07766, P09693, P20963 | PRKCQ, MAPK14, CD4, LCK, IL2RB, HLA-DOB, IL1R1, IL21R, TBX21, GATA3, SMAD4, HSP90AB1, CD3E, CD3G, CD247 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P42681 | TXK | Tyrosine-protein kinase TXK | Q04759 | PRKCQ | Protein kinase C theta type | 0.876 | P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q04759 | PRKCQ | Protein kinase C theta type | 0.803 | P51813 | BMX | Cytoplasmic tyrosine-protein kinase BMX | Q04759 | PRKCQ | Protein kinase C theta type | -0.737 | P51813 | BMX | Cytoplasmic tyrosine-protein kinase BMX | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.802 | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | P51813 | BMX | Cytoplasmic tyrosine-protein kinase BMX | P01730 | CD4 | T-cell surface glycoprotein CD4 | -0.857 | P42681 | TXK | Tyrosine-protein kinase TXK | P06239 | LCK | Tyrosine-protein kinase Lck | 0.734 | P07948 | LYN | Tyrosine-protein kinase Lyn | P06239 | LCK | Tyrosine-protein kinase Lck | -0.701 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P06239 | LCK | Tyrosine-protein kinase Lck | 0.774 | P51813 | BMX | Cytoplasmic tyrosine-protein kinase BMX | P06239 | LCK | Tyrosine-protein kinase Lck | -0.791 | P07948 | LYN | Tyrosine-protein kinase Lyn | P14784 | IL2RB | Interleukin-2 receptor subunit beta | -0.771 | P06239 | LCK | Tyrosine-protein kinase Lck | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.727 | P42681 | TXK | Tyrosine-protein kinase TXK | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.89 | P06239 | LCK | Tyrosine-protein kinase Lck | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.777 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.85 | P07948 | LYN | Tyrosine-protein kinase Lyn | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.714 | P06239 | LCK | Tyrosine-protein kinase Lck | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.782 | P51813 | BMX | Cytoplasmic tyrosine-protein kinase BMX | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.854 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q9HBE5 | IL21R | Interleukin-21 receptor | 0.713 | P42681 | TXK | Tyrosine-protein kinase TXK | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.849 | P07948 | LYN | Tyrosine-protein kinase Lyn | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.719 | P06239 | LCK | Tyrosine-protein kinase Lck | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.866 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.884 | P42681 | TXK | Tyrosine-protein kinase TXK | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.856 | P06239 | LCK | Tyrosine-protein kinase Lck | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.77 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.784 | P07948 | LYN | Tyrosine-protein kinase Lyn | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.729 | P07948 | LYN | Tyrosine-protein kinase Lyn | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | -0.782 | P07948 | LYN | Tyrosine-protein kinase Lyn | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | -0.824 | P06239 | LCK | Tyrosine-protein kinase Lck | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.928 | P51813 | BMX | Cytoplasmic tyrosine-protein kinase BMX | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | -0.755 | P42681 | TXK | Tyrosine-protein kinase TXK | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.838 | P06239 | LCK | Tyrosine-protein kinase Lck | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.752 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.813 | P42681 | TXK | Tyrosine-protein kinase TXK | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.811 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.839 | P51813 | BMX | Cytoplasmic tyrosine-protein kinase BMX | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.778 |
|
Revefenacin | hsa04660 | T cell receptor signaling pathway | 2.23E-09 | 15 | P01375, Q9UDY8, Q04759, P10747, O95267, Q08881, P07766, P20963, P09693, P01730, P01732, Q13191, P06239, Q16539, P49841 | TNF, MALT1, PRKCQ, CD28, RASGRP1, ITK, CD3E, CD247, CD3G, CD4, CD8A, CBLB, LCK, MAPK14, GSK3B | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P01375 | TNF | Tumor necrosis factor | -0.79 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q9UDY8 | MALT1 | Mucosa-associated lymphoid tissue lymphoma translocation protein 1 | 0.721 | P42681 | TXK | Tyrosine-protein kinase TXK | Q04759 | PRKCQ | Protein kinase C theta type | 0.876 | P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q04759 | PRKCQ | Protein kinase C theta type | 0.803 | P51813 | BMX | Cytoplasmic tyrosine-protein kinase BMX | Q04759 | PRKCQ | Protein kinase C theta type | -0.737 | P42681 | TXK | Tyrosine-protein kinase TXK | P10747 | CD28 | T-cell-specific surface glycoprotein CD28 | 0.776 | P42681 | TXK | Tyrosine-protein kinase TXK | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | 0.857 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | 0.925 | P42681 | TXK | Tyrosine-protein kinase TXK | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | 0.847 | P06239 | LCK | Tyrosine-protein kinase Lck | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | 0.774 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | 1 | P06239 | LCK | Tyrosine-protein kinase Lck | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.928 | P51813 | BMX | Cytoplasmic tyrosine-protein kinase BMX | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | -0.755 | P42681 | TXK | Tyrosine-protein kinase TXK | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.811 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.839 | P51813 | BMX | Cytoplasmic tyrosine-protein kinase BMX | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.778 | P42681 | TXK | Tyrosine-protein kinase TXK | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.838 | P06239 | LCK | Tyrosine-protein kinase Lck | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.752 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.813 | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | P51813 | BMX | Cytoplasmic tyrosine-protein kinase BMX | P01730 | CD4 | T-cell surface glycoprotein CD4 | -0.857 | P42681 | TXK | Tyrosine-protein kinase TXK | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.9 | P06239 | LCK | Tyrosine-protein kinase Lck | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.841 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.803 | P42681 | TXK | Tyrosine-protein kinase TXK | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | 0.716 | P06239 | LCK | Tyrosine-protein kinase Lck | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | 0.714 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | 0.811 | P42681 | TXK | Tyrosine-protein kinase TXK | P06239 | LCK | Tyrosine-protein kinase Lck | 0.734 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | P06239 | LCK | Tyrosine-protein kinase Lck | 0.774 | P51813 | BMX | Cytoplasmic tyrosine-protein kinase BMX | P06239 | LCK | Tyrosine-protein kinase Lck | -0.791 | P51813 | BMX | Cytoplasmic tyrosine-protein kinase BMX | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.802 | P51813 | BMX | Cytoplasmic tyrosine-protein kinase BMX | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.733 |
|
Revefenacin | hsa04662 | B cell receptor signaling pathway | 4.07E-02 | 4 | P42338, P60033, P07948, Q8N149 | PIK3CB, CD81, LYN, LILRA2 | More | |
Revefenacin | hsa04724 | Glutamatergic synapse | 2.22E-02 | 4 | O15399, P63218, P50151, P15104 | GRIN2D, GNG5, GNG10, GLUL | More | |
Revefenacin | hsa04727 | GABAergic synapse | 4.42E-02 | 3 | P63218, P50151, P15104 | GNG5, GNG10, GLUL | More | |
Revefenacin | hsa04728 | Dopaminergic synapse | 3.91E-02 | 5 | P50151, P49841, Q16539, P49407, P48058 | GNG10, GSK3B, MAPK14, ARRB1, GRIA4 | More | |
Revefenacin | hsa04730 | Long-term depression | 1.16E-02 | 1 | P08069 | IGF1R | More | |
Revefenacin | hsa04912 | GnRH signaling pathway | 3.19E-02 | 3 | Q08828, Q9Y6R4, P0DP23 | ADCY1, MAP3K4, CALM1 | More | |
Revefenacin | hsa04913 | Ovarian steroidogenesis | 8.40E-04 | 2 | P06213, P08069 | INSR, IGF1R | More | |
Revefenacin | hsa04914 | Progesterone-mediated oocyte maturation | 2.16E-02 | 1 | P08069 | IGF1R | More | |
Revefenacin | hsa04915 | Estrogen signaling pathway | 6.42E-03 | 4 | Q08828, P0DMV8, P0DP23, Q15788 | ADCY1, HSPA1A, CALM1, NCOA1 | More | |
Revefenacin | hsa04923 | Regulation of lipolysis in adipocytes | 3.76E-02 | 1 | P06213 | INSR | More | |
Revefenacin | hsa04924 | Renin secretion | 4.69E-02 | 2 | P07550, P0DP23 | ADRB2, CALM1 | More | |
Revefenacin | hsa04930 | Type II diabetes mellitus | 3.14E-02 | 1 | P06213 | INSR | More | |
Revefenacin | hsa04960 | Aldosterone-regulated sodium reabsorption | 3.14E-02 | 1 | P06213 | INSR | More | |
Revefenacin | hsa04964 | Proximal tubule bicarbonate reclamation | 4.48E-02 | 1 | P00918 | CA2 | More | |
Revefenacin | hsa04966 | Collecting duct acid secretion | 4.48E-02 | 1 | P00918 | CA2 | More | |
Revefenacin | hsa04970 | Salivary secretion | 1.60E-02 | 3 | P07550, Q08828, P0DP23 | ADRB2, ADCY1, CALM1 | More | |
Revefenacin | hsa05017 | Spinocerebellar ataxia | 2.22E-02 | 4 | Q92915, O15399, P42338, P21796 | FGF14, GRIN2D, PIK3CB, VDAC1 | More | |
Revefenacin | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 1.41E-02 | 4 | Q16539, P09341, P25024, P25025 | MAPK14, CXCL1, CXCR1, CXCR2 | More | |
Revefenacin | hsa05133 | Pertussis | 2.35E-03 | 2 | P0DP23, P0C0L4 | CALM1, C4A | More | |
Revefenacin | hsa05140 | Leishmaniasis | 3.53E-02 | 6 | P13612, O75015, P13765, O60603, P01375, Q15080 | ITGA4, FCGR3B, HLA-DOB, TLR2, TNF, NCF4 | More | |
Revefenacin | hsa05143 | African trypanosomiasis | 4.81E-02 | 2 | P69905, P68871 | HBA2, HBB | More | |
Revefenacin | hsa05144 | Malaria | 1.14E-02 | 5 | P60033, O60603, P01375, P35443, P26718 | CD81, TLR2, TNF, THBS4, KLRK1 | More | |
Revefenacin | hsa05146 | Amoebiasis | 1.65E-06 | 9 | P09341, P14778, P27930, P01375, O60603, P05089, P22694, P12814, P08311 | CXCL1, IL1R1, IL1R2, TNF, TLR2, ARG1, PRKACB, ACTN1, CTSG | More | |
Revefenacin | hsa05150 | Staphylococcus aureus infection | 1.31E-02 | 2 | P0C0L4, P13646 | C4A, KRT13 | More | |
Revefenacin | hsa05163 | Human cytomegalovirus infection | 1.63E-02 | 7 | P50151, P49841, P14778, Q13651, P25025, Q16539, O00463 | GNG10, GSK3B, IL1R1, IL10RA, CXCR2, MAPK14, TRAF5 | More | |
Revefenacin | hsa05169 | Epstein-Barr virus infection | 7.82E-04 | 13 | P13765, P01106, Q13547, O00463, P10415, P07948, Q13761, P24522, O60603, P29728, P07766, P09693, P20963 | HLA-DOB, MYC, HDAC1, TRAF5, BCL2, LYN, RUNX3, GADD45A, TLR2, OAS2, CD3E, CD3G, CD247 | More | |
Revefenacin | hsa05202 | Transcriptional misregulation in cancer | 2.67E-04 | 15 | Q13315, P41732, P14780, P27930, Q15744, Q16548, Q13077, O15550, P08069, P35226, P05164, P12838, P08246, Q9C0K0, P24522 | ATM, TSPAN7, MMP9, IL1R2, CEBPE, BCL2A1, TRAF1, UTX, IGF1R, BMI1, MPO, DEFA4, ELA2, BCL11B, GADD45A | More | |
Revefenacin | hsa05205 | Proteoglycans in cancer | 3.48E-02 | 1 | P08069 | IGF1R | More | |
Revefenacin | hsa05214 | Glioma | 9.95E-03 | 1 | P08069 | IGF1R | More | |
Revefenacin | hsa05215 | Prostate cancer | 1.33E-02 | 1 | P08069 | IGF1R | More | |
Revefenacin | hsa05218 | Melanoma | 6.63E-03 | 1 | P08069 | IGF1R | More | |
Revefenacin | hsa05224 | Breast cancer | 1.49E-02 | 1 | P08069 | IGF1R | More | |
Revefenacin | hsa05225 | Hepatocellular carcinoma | 1.33E-02 | 1 | P08069 | IGF1R | More | |
Revefenacin | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 9.93E-07 | 10 | O95267, P07766, P20963, P09693, P06239, O60603, P10747, Q04759, Q16539, P01730 | RASGRP1, CD3E, CD247, CD3G, LCK, TLR2, CD28, PRKCQ, MAPK14, CD4 | More | |
Revefenacin | hsa05310 | Asthma | 1.92E-02 | 3 | P13765, P12724, P01375 | HLA-DOB, RNASE3, TNF | More | |
Revefenacin | hsa05321 | Inflammatory bowel disease | 6.95E-07 | 7 | O60603, P01375, P13765, Q14765, Q9UL17, P23771, Q9HBE5 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3, IL21R | More | |
Revefenacin | hsa05323 | Rheumatoid arthritis | 2.19E-02 | 4 | P13765, P10747, P09341, O60603 | HLA-DOB, CD28, CXCL1, TLR2 | More | |
Revefenacin | hsa05332 | Graft-versus-host disease | 2.87E-05 | 5 | P13765, P10747, P01375, P26715, Q13241 | HLA-DOB, CD28, TNF, KLRC1, KLRD1 | More | |
Revefenacin | hsa05340 | Primary immunodeficiency | 2.19E-02 | 4 | P01730, P01732, P07766, P06239 | CD4, CD8A, CD3E, LCK | More | |
Revefenacin | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.48E-02 | 1 | P54284 | CACNB3 | More | |
Revefenacin | hsa05414 | Dilated cardiomyopathy | 4.55E-02 | 2 | P54284, P26678 | CACNB3, PLN | More | |